{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:10:45Z","timestamp":1777475445757,"version":"3.51.4"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/mop.0000000000000093","type":"journal-article","created":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T11:26:01Z","timestamp":1397129161000},"page":"383-395","source":"Crossref","is-referenced-by-count":18,"title":["Child and adolescent immunizations"],"prefix":"10.1097","volume":"26","author":[{"given":"Carol M.","family":"Kao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca J.","family":"Schneyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Bocchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20-20210206","first-page":"473","article-title":"States, 2012-13 season and composition of the 2013-14 influenza vaccine.","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"RR-07","key":"R3-20-20210206","first-page":"1","article-title":"Recommendations of the Advisory Committee on Immunization Practices - United States, 2013-2014.","volume":"62","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"R4-20-20210206","doi-asserted-by":"crossref","first-page":"e1089","DOI":"10.1542\/peds.2013-2377","article-title":"","volume":"132","year":"2013","journal-title":"Pediatrics"},{"key":"R5-20-20210206","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/infdis\/jit091","article-title":"A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.","volume":"207","author":"Domachowske","year":"2013","journal-title":"J Infect Dis"},{"key":"R6-20-20210206","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/infdis\/jit263","article-title":"Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children.","volume":"208","author":"Langley","year":"2013","journal-title":"J Infect Dis"},{"key":"R7-20-20210206","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/INF.0b013e31825687b0","article-title":"Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children.","volume":"31","author":"Block","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R8-20-20210206","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.vaccine.2011.12.098","article-title":"Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine.","volume":"30","author":"Reed","year":"2012","journal-title":"Vaccine"},{"key":"R9-20-20210206","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.1016\/j.vaccine.2012.10.025","article-title":"The economic value of a quadrivalent versus trivalent influenza vaccine.","volume":"30","author":"Lee","year":"2012","journal-title":"Vaccine"},{"key":"R10-20-20210206","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.anai.2012.09.011","article-title":"Safe administration of the seasonal trivalent influenza vaccine to children with severe egg allergy.","volume":"109","author":"Greenhawt","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R11-20-20210206","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jaci.2012.07.046","article-title":"PCIRN (Public Health Agency of CanadaCanadian Institutes of Health Research Influenza Research Network)Egg-allergic patients can be safely vaccinated against influenza.","volume":"130","author":"Des Roches","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"R12-20-20210206","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/INF.0b013e31824bb179","article-title":"Reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.","volume":"31","author":"Vesikari","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R15-20-20210206","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1471-2431-13-180","article-title":"Factors associated with in-office influenza vaccination by U.S. pediatric providers.","volume":"13","author":"Lin","year":"2013","journal-title":"BMC Pediatr"},{"key":"R16-20-20210206","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1542\/peds.2010-2376","article-title":"American Academy of PediatricsCommittee on Infectious Diseases. Policy statement - recommendation for mandatory influenza immunization of all healthcare personnel.","volume":"126","author":"Bernstein","year":"2010","journal-title":"Pediatrics"},{"key":"R17-20-20210206","first-page":"781","article-title":"States, 2012-13 influenza season.","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R18-20-20210206","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1086\/656210","article-title":"Mandatory influenza vaccination of healthcare workers: a 5-year study.","volume":"31","author":"Rakita","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R19-20-20210206","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1086\/663210","article-title":"Voluntary to mandatory: evolution of strategies and attitudes toward influenza vaccination of healthcare personnel.","volume":"33","author":"Quan","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R20-20-20210206","doi-asserted-by":"crossref","first-page":"9398","DOI":"10.1016\/j.vaccine.2011.09.047","article-title":"Increases in vaccination coverage of healthcare personnel following institutional requirements for influenza vaccination: a national survey of U.S. hospitals.","volume":"29","author":"Miller","year":"2011","journal-title":"Vaccine"},{"key":"R21-20-20210206","first-page":"52","article-title":"Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale.","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"RR-2","key":"R22-20-20210206","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC)Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"R23-20-20210206","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/INF.0b013e3182840e35","article-title":"Antibody persistence for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) given at 12-15 months of age.","volume":"32","author":"Marshall","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R26-20-20210206","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4161\/hv.27051","article-title":"Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.","volume":"10","author":"Nolan","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"R27-20-20210206","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"EU Meningococcal B Infant Vaccine Study groupImmunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"R28-20-20210206","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.","volume":"185","author":"Snape","year":"2013","journal-title":"CMAJ"},{"key":"R30-20-20210206","first-page":"685","article-title":"13-17 years - United States, 2012.","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R31-20-20210206","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/0009922813481847","article-title":"Awareness is not enough: the need to increase meningococcal vaccine uptake.","volume":"52","author":"Coyne-Beasley","year":"2013","journal-title":"Clin Pediatr (Phila)"},{"key":"R32-20-20210206","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1016\/j.vaccine.2012.06.005","article-title":"Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborn and healthcare workers): a review of evidence and recommendations.","volume":"30","author":"Bechini","year":"2012","journal-title":"Vaccine"},{"key":"R33-20-20210206","doi-asserted-by":"crossref","first-page":"e1047","DOI":"10.1542\/peds.2012-1928","article-title":"Waning immunity to pertussis following 5 doses of DTaP.","volume":"131","author":"Tartof","year":"2013","journal-title":"Pediatrics"},{"key":"R34-20-20210206","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.vaccine.2012.11.052","article-title":"Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy.","volume":"31","author":"Wiley","year":"2013","journal-title":"Vaccine"},{"key":"R35-20-20210206","first-page":"131","article-title":"Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap) in Pregnant Women- Advisory Committee on Immunization Practices (ACIP), 2012.","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R36-20-20210206","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1056\/NEJMoa1200850","article-title":"Waning protection after fifth dose of acellular pertussis vaccine in children.","volume":"367","author":"Klein","year":"2012","journal-title":"N Engl J Med"},{"key":"R37-20-20210206","doi-asserted-by":"crossref","first-page":"e1716","DOI":"10.1542\/peds.2012-3836","article-title":"Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers.","volume":"131","author":"Klein","year":"2013","journal-title":"Pediatrics"},{"key":"R38-20-20210206","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1016\/j.vaccine.2010.09.034","article-title":"The safety of immunizing with tetanus-diphtheria-acellular pertussis less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak.","volume":"28","author":"Talbot","year":"2010","journal-title":"Vaccine"},{"key":"R42-20-20210206","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/cid\/cis923","article-title":"Importance of timing of maternal combined tetanus, diphtheria and pertussis immunization and protection of young infants.","volume":"56","author":"Healy","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R43-20-20210206","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1097\/INF.0b013e3182a09b6a","article-title":"Immune response in infants whose mothers received Tdap vaccine during pregnancy.","volume":"32","author":"Hardy-Fairbanks","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R44-20-20210206","doi-asserted-by":"crossref","first-page":"e1748","DOI":"10.1542\/peds.2012-3144","article-title":"Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis.","volume":"131","author":"Terranella","year":"2013","journal-title":"Pediatrics"},{"issue":"RR-11","key":"R45-20-20210206","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC)Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine- recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"59","author":"Nuorti","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"R46-20-20210206","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1542\/peds.2012-3900","article-title":"Invasive pneumococcal disease in infants younger than 90 days before and after introduction of PCV7.","volume":"132","author":"Olarte","year":"2013","journal-title":"Pediatrics"},{"key":"R47-20-20210206","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/INF.0b013e318275614b","article-title":"Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine.","volume":"32","author":"Kaplan","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R48-20-20210206","first-page":"253","article-title":"13-valent pneumococcal conjugate vaccine - United States, 2007.","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R49-20-20210206","first-page":"521","article-title":"13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R50-20-20210206","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamapediatrics.2013.3924","article-title":"Trends in otitis media-related healthcare use in the United States, 2001-2011.","volume":"168","author":"Marom","year":"2014","journal-title":"JAMA Pediatr"},{"key":"R51-20-20210206","first-page":"e498","article-title":"Pneumococcal conjugate vaccine: are 3 doses equal to 4 doses P","volume":"132","author":"Walter","year":"2013","journal-title":"ediatrics"},{"key":"R52-20-20210206","first-page":"733","article-title":"National, state, and local area vaccination coverage among children aged 19-35 months - United States, 2012.","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R53-20-20210206","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1542\/peds.2012-3350","article-title":"Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine.","volume":"132","author":"Stoecker","year":"2013","journal-title":"Pediatrics"},{"key":"R54-20-20210206","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1016\/j.vaccine.2012.08.011","article-title":"7-Valent pneumococcal conjugate vaccine and otitis media: effectiveness of a 2-dose versus 3-dose primary series.","volume":"30","author":"Stoecker","year":"2012","journal-title":"Vaccine"},{"key":"R55-20-20210206","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.vaccine.2009.11.053","article-title":"7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series.","volume":"28","author":"Pelton","year":"2010","journal-title":"Vaccine"},{"key":"R56-20-20210206","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1016\/j.vaccine.2013.10.042","article-title":"Effectiveness of 21 PCV7 vaccination schedules in children under 2 years: a meta-analysis of impact studies.","volume":"31","author":"Schonberger","year":"2013","journal-title":"Vaccine"},{"key":"R57-20-20210206","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/INF.0b013e3181cffa2a","article-title":"Effectiveness of pneumococcal conjugate vaccine using a 211 infant schedule in Quebec, Canada.","volume":"29","author":"Deceuninck","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R58-20-20210206","doi-asserted-by":"crossref","first-page":"9711","DOI":"10.1016\/j.vaccine.2011.07.042","article-title":"Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis.","volume":"29","author":"Scott","year":"2011","journal-title":"Vaccine"},{"key":"R59-20-20210206","first-page":"591","article-title":"Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States.","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R60-20-20210206","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/infdis\/jit192","article-title":"Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.","volume":"208","author":"Markowitz","year":"2013","journal-title":"J Infect Dis"},{"key":"R61-20-20210206","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.2105\/AJPH.2012.301182","article-title":"Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination.","volume":"103","author":"Flagg","year":"2013","journal-title":"Am J Public Health"},{"key":"R62-20-20210206","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1542\/peds.2012-2384","article-title":"Reasons for not vaccinating adolescents: National Immunization Survey of Teens, 2008-2010.","volume":"131","author":"Darden","year":"2013","journal-title":"Pediatrics"},{"key":"R63-20-20210206","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1016\/j.vaccine.2013.07.033","article-title":"Human papillomavirus vaccine communication: perspectives of 11-12 year-old girls, mothers, and clinicians.","volume":"31","author":"Mullins","year":"2013","journal-title":"Vaccine"},{"key":"R64-20-20210206","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.vaccine.2013.04.010","article-title":"HPV vaccination among adolescent males: results from the National Immunization Survey-Teen.","volume":"31","author":"Reiter","year":"2013","journal-title":"Vaccine"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000000093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:28:36Z","timestamp":1620962916000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201406000-00020"}},"subtitle":["selected review of recent US recommendations and literature"],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000093","relation":{},"ISSN":["1040-8703"],"issn-type":[{"value":"1040-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}